Hyundai Bio expands pipeline for long covid and cervical cancer, antiviral drug ‘CP-COV03’

Provided by Hyundai Bio

Hyundai Bio announced on the 8th that it was smoothly conducting a long-term administration toxicity test by selecting ‘DTNCRO’, a non-clinical institution, as a test institution to expand the indications for CP-COV03 to various viral diseases other than COVID-19.

Prior to the long-term dosing experiment, Hyundai Bio conducted preliminary animal tests from April to June of this year, and explained that no side effects were observed as a result of administering a high dose of 900 mg/kg per day for about a month.

900mg/kg is equivalent to 54g for a person weighing 60kg, but if you apply 1/6 times the difference in body surface area by species, it is calculated that there is no toxicity even if you administer 9g a day to humans. This amounts to 10 times the daily low dose (900mg) and 6.7 times the high dose (1,350mg) administered to patients in the ongoing phase 2 COVID-19 clinical trial of CP-COV03.

Drug repositioning has the advantage of significantly reducing the cost and period of drug development by changing the use of a drug approved or under development as a treatment for a specific disease to a new treatment for a disease.

Hyundai Bio said that the possibility of CP-COV03’s coronal clinical success is increasing, and that it is actively promoting the expansion of indications based on the mechanism (mechanism) in which CP-COV03 exhibits superior safety and broad efficacy compared to existing antiviral drugs.

Hyundai Bio announced that it is considering ‘Long Covid’, ‘HPV (human papillomavirus)’ that causes cervical cancer, and ‘monkeypox’ as the priority targets for expanding the indications for CP-COV03. The mid- to long-term targets include dengue fever, tick virus, and AIDS.

Recently, a research team at Harvard University School of Medicine in the United States announced the results of a study that found that the spike protein for penetrating the protrusion-shaped cells that make up the envelope of the Corona 19 virus was detected in the blood of 60% of patients with Long Corvid symptoms up to 12 months after infection. . The World Health Organization (WHO) defines long covid as various symptoms that persist for at least two months after being confirmed with COVID-19, and it is estimated that 10-30% of all confirmed patients experience it.

CP-COV03, which has niclosamide as its main ingredient, has a ‘cell targeting’ mechanism that promotes ‘autophagy’ when a virus invades a cell and induces the cell to eliminate the virus. Existing antiviral drugs for COVID-19 that inhibit virus replication improve symptoms only after a certain period of time after administration, whereas CP-COV03 shows rapid improvement in symptoms after administration and has medicinal effects on the virus remaining in the body. This is expected, the company said.

A Hyundai Bio official said, “The number and duration of administration of the same drug is strictly limited because long-term administration of existing antiviral agents that target a specific virus causes drug resistance to the virus.” Unlike existing antiviral drugs, it is the most suitable drug for longcovid treatment because it is free from drug resistance and mutation of the virus.”

He added, “Once the long-term dosing experiment is completed, the use of CP-COV03 can be more easily expanded from a treatment for COVID-19 (brand name ‘Zefty’) to Longcovid, monkeypox, and HPV treatment.”

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.